vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and GENESIS ENERGY LP (GEL). Click either name above to swap in a different company.

CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($749.2M vs $440.8M, roughly 1.7× GENESIS ENERGY LP). GENESIS ENERGY LP runs the higher net margin — 4.5% vs 3.6%, a 0.9% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (62.0% vs 10.5%). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (45.0% CAGR vs 0.7%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Genesis Energy LP is a U.S.-based midstream energy limited partnership that operates critical infrastructure for crude oil, natural gas, refined petroleum products, and specialty industrial materials. Its core assets include pipelines, storage terminals, marine facilities, and rail logistics hubs, serving refineries, industrial clients, and energy distributors across North America.

CLOV vs GEL — Head-to-Head

Bigger by revenue
CLOV
CLOV
1.7× larger
CLOV
$749.2M
$440.8M
GEL
Growing faster (revenue YoY)
CLOV
CLOV
+51.6% gap
CLOV
62.0%
10.5%
GEL
Higher net margin
GEL
GEL
0.9% more per $
GEL
4.5%
3.6%
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
45.0%
0.7%
GEL

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CLOV
CLOV
GEL
GEL
Revenue
$749.2M
$440.8M
Net Profit
$27.3M
$19.9M
Gross Margin
Operating Margin
3.6%
20.4%
Net Margin
3.6%
4.5%
Revenue YoY
62.0%
10.5%
Net Profit YoY
140.2%
EPS (diluted)
$0.05
$0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
GEL
GEL
Q1 26
$749.2M
Q4 25
$487.7M
$440.8M
Q3 25
$496.6M
$414.0M
Q2 25
$477.6M
$377.3M
Q1 25
$462.3M
$398.3M
Q4 24
$337.0M
$398.9M
Q3 24
$331.0M
$397.3M
Q2 24
$356.3M
$430.2M
Net Profit
CLOV
CLOV
GEL
GEL
Q1 26
$27.3M
Q4 25
$-49.3M
$19.9M
Q3 25
$-24.4M
$9.2M
Q2 25
$-10.6M
$-406.0K
Q1 25
$-1.3M
$-469.1M
Q4 24
$-22.1M
$-49.4M
Q3 24
$-9.2M
$-17.2M
Q2 24
$7.4M
$-8.7M
Gross Margin
CLOV
CLOV
GEL
GEL
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
24.5%
Q2 24
30.3%
Operating Margin
CLOV
CLOV
GEL
GEL
Q1 26
3.6%
Q4 25
-10.1%
20.4%
Q3 25
-4.9%
19.0%
Q2 25
-2.2%
17.9%
Q1 25
-0.3%
5.5%
Q4 24
-6.4%
3.4%
Q3 24
-2.7%
12.2%
Q2 24
2.0%
11.6%
Net Margin
CLOV
CLOV
GEL
GEL
Q1 26
3.6%
Q4 25
-10.1%
4.5%
Q3 25
-4.9%
2.2%
Q2 25
-2.2%
-0.1%
Q1 25
-0.3%
-117.8%
Q4 24
-6.6%
-12.4%
Q3 24
-2.8%
-4.3%
Q2 24
2.1%
-2.0%
EPS (diluted)
CLOV
CLOV
GEL
GEL
Q1 26
$0.05
Q4 25
$0.04
Q3 25
$-0.05
Q2 25
$-0.12
Q1 25
$-4.06
Q4 24
$-0.58
Q3 24
$-0.32
Q2 24
$-0.25

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
GEL
GEL
Cash + ST InvestmentsLiquidity on hand
$177.6M
$6.4M
Total DebtLower is stronger
$3.0B
Stockholders' EquityBook value
$339.4M
Total Assets
$697.7M
$4.9B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
GEL
GEL
Q1 26
$177.6M
Q4 25
$78.3M
$6.4M
Q3 25
$4.9M
Q2 25
$4.5M
Q1 25
$377.4M
Q4 24
$194.5M
$7.4M
Q3 24
$288.0M
$13.0M
Q2 24
$254.8M
$13.7M
Total Debt
CLOV
CLOV
GEL
GEL
Q1 26
Q4 25
$3.0B
Q3 25
$3.1B
Q2 25
$3.1B
Q1 25
$3.4B
Q4 24
$3.7B
Q3 24
$4.0B
Q2 24
$3.9B
Stockholders' Equity
CLOV
CLOV
GEL
GEL
Q1 26
$339.4M
Q4 25
$308.7M
Q3 25
$340.9M
Q2 25
$344.2M
Q1 25
$336.1M
Q4 24
$341.1M
Q3 24
$342.2M
Q2 24
$324.9M
Total Assets
CLOV
CLOV
GEL
GEL
Q1 26
$697.7M
Q4 25
$541.0M
$4.9B
Q3 25
$559.7M
$4.9B
Q2 25
$575.0M
$4.8B
Q1 25
$583.7M
$5.2B
Q4 24
$580.7M
$7.0B
Q3 24
$653.0M
$7.1B
Q2 24
$674.2M
$7.0B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
GEL
GEL
Operating Cash FlowLast quarter
$110.8M
Free Cash FlowOCF − Capex
$87.0M
FCF MarginFCF / Revenue
19.7%
Capex IntensityCapex / Revenue
5.4%
Cash ConversionOCF / Net Profit
5.58×
TTM Free Cash FlowTrailing 4 quarters
$65.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
GEL
GEL
Q1 26
Q4 25
$-66.9M
$110.8M
Q3 25
$12.1M
$70.3M
Q2 25
$5.4M
$47.0M
Q1 25
$-16.3M
$24.8M
Q4 24
$34.8M
$74.0M
Q3 24
$50.0M
$87.3M
Q2 24
$44.8M
$104.7M
Free Cash Flow
CLOV
CLOV
GEL
GEL
Q1 26
Q4 25
$-69.0M
$87.0M
Q3 25
$11.4M
$43.3M
Q2 25
$4.8M
$-7.6M
Q1 25
$-16.5M
$-56.8M
Q4 24
$33.3M
$-47.1M
Q3 24
$49.6M
$-32.3M
Q2 24
$44.4M
$-67.5M
FCF Margin
CLOV
CLOV
GEL
GEL
Q1 26
Q4 25
-14.1%
19.7%
Q3 25
2.3%
10.5%
Q2 25
1.0%
-2.0%
Q1 25
-3.6%
-14.3%
Q4 24
9.9%
-11.8%
Q3 24
15.0%
-8.1%
Q2 24
12.5%
-15.7%
Capex Intensity
CLOV
CLOV
GEL
GEL
Q1 26
Q4 25
0.4%
5.4%
Q3 25
0.1%
6.5%
Q2 25
0.1%
14.5%
Q1 25
0.0%
20.5%
Q4 24
0.5%
30.3%
Q3 24
0.1%
30.1%
Q2 24
0.1%
40.0%
Cash Conversion
CLOV
CLOV
GEL
GEL
Q1 26
Q4 25
5.58×
Q3 25
7.63×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
6.04×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLOV
CLOV

Segment breakdown not available.

GEL
GEL

Onshore Facilities And Transportation Revenue$204.2M46%
Offshore Pipeline Transportation Revenue$154.3M35%
Marine Transportation Revenue$82.2M19%

Related Comparisons